NCT06425055已完成2 期
Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Enyo Pharma
- 入组人数
- 26
- 试验地点
- 13
- 主要终点
- Number of Treatment-Emergent Adverse Event (TEAE)
研究概览
简要总结
This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.
详细描述
This is a multicenter study and several clinical sites and countries will be involved.
This single arm, fixed dose escalation, open-label, non-randomized study will evaluate three dose levels of vonafexor on safety, tolerability and their effect on kidney function and renal biomarkers in 20 patients with AS at risk of progression.
The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent (also for legal representatives, as applicable in the US for under eighteen patients).
- •Has confirmed diagnosis of Alport syndrome: clinical diagnosis (haematuria, family history, hearing loss, ocular change) OR a kidney biopsy showing glomerular basement membrane abnormalities consistent with AS, AND Genetic confirmation of AS.
- •Has eGFR between ≥ 30 and < 90 ml/min/1.73m
- •Has increased albuminuria criteria i.e. UACR ≥ 300 mg/g.
- •If on an angiotensin converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB), should be on a stable well tolerated treatment during at least the 60 days prior D
- •If on Sodium-Glucose Transport Protein 2 (SGLT2), should be on stable well tolerated treatment with SGLT2 during at least 60 days prior D
- •If patient has a history of arterial hypertension, should be on stable anti-hypertensive therapy for at least 60 days prior to D1 and deemed controlled by the investigator at screening and D
- •Sexually active female subjects of childbearing potential and sexually mature male subjects must use two acceptable effective methods of contraception for the entire duration of the study and for at least 6 weeks after last dose.
- •Has negative results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV).
- •Is able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol.
排除标准
- •Is an employee of a site, clinical research organization, vendor, or sponsor involved with this study.
- •Is pregnant or breastfeeding.
- •Has participated in any investigational drug study within 60 days prior to D
- •Any clinically significant illness within 30 days before D1 or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety.
- •Any history of active malignancy within the last 1 year before D
- •Any other condition or circumstance that, in the opinion of the investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety and well-being.
- •Has a history of an allergic condition that required the prescription of an emergency epinephrine injection (such as the EpiPen® Auto-Injector).
- •Any prohibited co-medications within 30 days prior D
- •Has ALT or AST above near normal (>1.5×ULN) at baseline.
- •Are at high risk for atherosclerotic cardiovascular disease (ASCVD) risk, with an LDL-C level > 160 mg/dL (4.15 mmol/L) and subjects at intermediate risk for ASCVD risk, with a LDL-C level > 190 mg/dL (4.91 mmol/L).
- •Has moderate or severe hepatic impairment (Child-Pugh score B or C).
- •Is taking CYP3A4/5 inhibitors or inducers.
研究组 & 干预措施
Single arm fixed dose escalation
Experimental
This is a single arm fixed dose escalation with three dose levels of vonafexor, all QD.
干预措施: Vonafexor (Drug)
结局指标
主要结局
Number of Treatment-Emergent Adverse Event (TEAE)
时间窗: From first dose of treatment until 2 weeks after last dose of treatment, i.e assessed up to 26 weeks
To assess the safety and tolerability of vonafexor
次要结局
- Vonafexor plasma concentrations(During on-treatment period, assessed up to 24 weeks)
- Change in eGFR(During on-treatment (assessed up to 24 weeks) and off-treatment periods (assessed up to 36 weeks) compared to baseline)
研究者
研究点 (13)
Loading locations...
相似试验
进行中（未招募）
1 期
Vonafexor in Impaired Renal Function and Suspected MASHImpaired renal function and suspected MASHCTIS2023-509192-16-00ENYO Pharma50
已完成
2 期
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)Non-alcoholic SteatohepatitisNCT03812029Enyo Pharma120
已完成
1 期
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesLeukemia, Lymphocytic, AcuteLeukemia, Nonlymphocytic, AcuteLeukemia, Myeloid, ChronicMyelodysplastic SyndromesNCT00246662Sunesis Pharmaceuticals75
已完成
不适用
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral SuppressionAIDSHIV InfectionsNCT00344981University of Maryland, Baltimore9
已完成
4 期
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 PatientsHIV InfectionsNCT00106379Gilead Sciences52